Antibiotics in the clinical pipeline in 2011

被引：204

作者：

Butler, Mark S. ^{[1
]}

Cooper, Matthew A. ^{[1
]}

机构：

[1] Univ Queensland, Div Chem & Struct Biol, Inst Mol Biosci, Brisbane, Qld 4072, Australia

来源：

JOURNAL OF ANTIBIOTICS | 2011年 / 64卷 / 06期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

clinical trials; drug development; drug discovery; natural product; resistance; IN-VITRO ACTIVITIES; PEPTIDE DEFORMYLASE INHIBITOR; CARRIER PROTEIN REDUCTASE; TRANSFER-RNA SYNTHETASE; DE-NOVO DESIGN; STAPHYLOCOCCUS-AUREUS; FABI INHIBITOR; LIPID-II; BAD BUGS; MYCOBACTERIUM-TUBERCULOSIS;

D O I：

10.1038/ja.2011.44

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The emergence of multi-drug-resistant bacteria and the lack of new antibiotics in the antibiotic drug development pipeline, especially those with new modes of action, is a major health concern. This review lists the 20 new antibiotics launched since 2000 and records the 40 compounds currently in active clinical development. Compounds in the pipeline from new antibiotic classes are reviewed in detail with reference to their development status, mode of action, spectrum of activity and lead discovery. In addition, the NP or synthetic derivation is discussed, with activity against Gram-negative bacteria highlighted. The Journal of Antibiotics (2011) 64, 413-425; doi:10.1038/ja.2011.44; published online 18 May 2011

引用

页码：413 / 425

页数：13

共 201 条

[1]

*AFF PHARM, AFF PHARM PROGR OV

[2] Synthesis and Spectrum of the Neoglycoside ACHN-490 [J].

Aggen, James B. ;

Armstrong, Eliana S. ;

Goldblum, Adam A. ;

Dozzo, Paola ;

Linsell, Martin S. ;

Gliedt, Micah J. ;

Hildebrandt, Darin J. ;

Feeney, Lee Ann ;

Kubo, Aya ;

Matias, Rowena D. ;

Lopez, Sara ;

Gomez, Marcela ;

Wlasichuk, Kenneth B. ;

Diokno, Raymond ;

Miller, George H. ;

Moser, Heinz E. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (11) :4636-4642

[3] PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis [J].

Ahmad, Zahoor ;

Peloquin, Charles A. ;

Singh, Rajendra P. ;

Derendorf, Hartmut ;

Tyagi, Sandeep ;

Ginsberg, Ann ;

Grosset, Jacques H. ;

Nuermberger, Eric L. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (01) :239-245

[4]

Allen Norris E., 2010, Anti-Infective Agents in Medicinal Chemistry, V9, P23

[5] In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms [J].

Almer, LS ;

Hoffrage, JB ;

Keller, EL ;

Flamm, RK ;

Shortridge, VD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2771-2777

[6] A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].

Andries, K ;

Verhasselt, P ;

Guillemont, J ;

Göhlmann, HWH ;

Neefs, JM ;

Winkler, H ;

Van Gestel, J ;

Timmerman, P ;

Zhu, M ;

Lee, E ;

Williams, P ;

de Chaffoy, D ;

Huitric, E ;

Hoffner, S ;

Cambau, E ;

Truffot-Pernot, C ;

Lounis, N ;

Jarlier, V .

SCIENCE, 2005, 307 (5707) :223-227

[7]

[Anonymous], 2009, MED NEWS TODAY

[8] Nemonoxacin Quinolone antibiotic [J].

Arjona, A. .

DRUGS OF THE FUTURE, 2009, 34 (03) :196-203

[9] Combating evolution with intelligent design: the neoglycoside ACHN-490 [J].

Armstrong, Eliana S. ;

Miller, George H. .

CURRENT OPINION IN MICROBIOLOGY, 2010, 13 (05) :565-573

[10] STRUCTURE ELUCIDATION OF THE MACROCYCLIC ANTIBIOTIC LIPIARMYCIN [J].

ARNONE, A ;

NASINI, G ;

CAVALLERI, B .

JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1987, (06) :1353-1359

← 1 2 3 4 5 6 7 8 9 10 →